MTOR and hepatocellular carcinoma: Functionally, we found that the pro-metastatic effect of TCF7L2 on HCC could be reversed by AKT or mTOR inhibitors, indicating that TCF7L2 plays a role in HCC by activating the AKT/mTOR pathway.